Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting

[1] Cheah AL(2013)Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization Clin Microbiol Infect 19 E181-E189

[2] Spelman T(2014)Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia BMC Infect Dis 14 353-1000

[3] Liew D(1995)Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections J Infect Dis 172 993-770

[4] Peel T(2012)Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation Clin Infect Dis 55 764-2458

[5] Howden BP(2012)Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia Antimicrob Agents Chemother 56 2452-2865

[6] Spelman D(2014)The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients Leuk Lymphoma 55 2858-333

[7] Cheah AL(2005)Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis Clin Infect Dis 41 327-35

[8] Peel T(2010)Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort Infect Control Hosp Epidemiol 31 28-3458

[9] Howden BP(2016)Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency J Antimicrob Chemother 71 3453-2447

[10] Spelman D(2016)Resistance mechanisms, epidemiology, and approaches to screening for Vancomycin-resistant Enterococcus in the health care setting J Clin Microbiol 54 2436-707

[1] Cheah AL(2013)Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization Clin Microbiol Infect 19 E181-E189

[2] Spelman T(2014)Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia BMC Infect Dis 14 353-1000

[3] Liew D(1995)Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections J Infect Dis 172 993-770

[4] Peel T(2012)Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation Clin Infect Dis 55 764-2458

[5] Howden BP(2012)Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia Antimicrob Agents Chemother 56 2452-2865

[6] Spelman D(2014)The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients Leuk Lymphoma 55 2858-333

[7] Cheah AL(2005)Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis Clin Infect Dis 41 327-35

[8] Peel T(2010)Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort Infect Control Hosp Epidemiol 31 28-3458

[9] Howden BP(2016)Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency J Antimicrob Chemother 71 3453-2447

[10] Spelman D(2016)Resistance mechanisms, epidemiology, and approaches to screening for Vancomycin-resistant Enterococcus in the health care setting J Clin Microbiol 54 2436-707